Latest filingSep 03, 2026Most recent Form 4
FDMT
4D Molecular Therapeutics, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$113M5 sells
Net open-market-$113M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period13transactions
- M · Option exercise · dominant8 · 62%
- S · Open-market sells5 · 38%
Activity by reported role
A joint filing can contribute to multiple roles13transactions
- CLO · dominant9 · 69%
- SR4 · 31%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeBizily ScottCommon Stock · Direct
9,201Sep 01, 2026
Bizily ScottStock Option (Right to Buy) · Direct
2,959Sep 01, 2026
Kirn DavidCommon Stock · Direct
825,819Aug 19, 2026
Kirn DavidStock Option (Right to Buy) · Direct
217,500Aug 19, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- KD-$1.1M
- BS-$47.7k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
FDMT transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| FDMT | Bizily Scott | CLO | sale10b5-1 | 584 | -$817k | S | — | 0.0% | 09/03 | 09/01 |
| FDMT | Kirn David | SR | sale10b5-1 | 25.9k | -$42.5M | S | −7.3% | 08/21 | 08/19 | |
| FDMT | Kirn David | SR | sale10b5-1 | 43.1k | -$66.2M | S | −7.3% | 08/21 | 08/19 | |
| FDMT | Bizily Scott | CLO | sale10b5-1 | 1.63k | -$1.99M | S | −1.3% | 08/17 | 08/17 | |
| FDMT | Bizily Scott | CLO | sale10b5-1 | 1.63k | -$1.96M | S | −1.3% | 08/17 | 08/13 |
4D Molecular Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at 4D Molecular Therapeutics, Inc.?
Bizily Scott, Kirn David.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Bizily Scott reported a sale on Sep 01, 2026 valued at $817k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,136,016.27. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.